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Abstract: Multiple myeloma (MM) is a malignancy of plasma cells characterized by multifocal
osteolytic bone lesions. Macroscopic and genetic heterogeneity has been documented within
MM lesions. Understanding the bases of such heterogeneity may unveil relevant features of
MM pathobiology. To this aim, we deployed unbiased 1 H high-resolution magic-angle spinning
(HR-MAS) nuclear magnetic resonance (NMR) metabolomics to analyze multiple biopsy specimens
of osteolytic lesions from one case of pathological fracture caused by MM. Multivariate analyses
on normalized metabolite peak integrals allowed clusterization of samples in accordance with
a posteriori histological findings. We investigated the relationship between morphological and
NMR features by merging morphological data and metabolite profiling into a single correlation
matrix. Data-merging addressed tissue heterogeneity, and greatly facilitated the mapping of lesions
and nearby healthy tissues. Our proof-of-principle study reveals integrated metabolomics and
histomorphology as a promising approach for the targeted study of osteolytic lesions.
Keywords: high-resolution magic-angle spinning (HR-MAS); metabolomics; multiple myeloma;
nuclear magnetic resonance (NMR); osteolysis
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1. Introduction
Cancer-induced bone disease is one of the commonest and most severe complications in cancer,
leading to severe pain, compression, and fractures, with a profound impact on quality of life, morbidity,
and survival. Frequently attracted to skeletal sites, cancer cells establish vicious interactions with the
bone microenvironment, occupying functional niches and exploiting local homeostatic factors to gain
fitness, drug resistance, and growth support. Multiple myeloma (MM) is a cancer of bone marrow
resident plasma cells, which grow abnormally at multiple skeletal sites and subvert physiologic bone
remodeling by suppressing osteoblastic bone formation and promoting osteoclastic bone resorption,
thereby inducing systemic bone loss and multifocal bone destruction [1,2].
Skeletal cancer lesions experience heterogeneous metabolic conditions owing to different
vascularization, pH, and mechanical strain. From a clinical standpoint, the evaluation of individual
lesions is important to prevent severe complications such as skeletal-related events. Recent evidence
demonstrated genetic heterogeneity within the same tumor lesion, which may explain tumor
progression and resistance to treatment [3]. Understanding such heterogeneity may help understand
the pathobiology of cancer-induced bone disease in order to develop novel therapeutic targets.
Metabolomics, the comprehensive assessment of small metabolites in a biological system, has been
shown to provide relevant insights in complex diseases, with many potential clinical applications [4–6].
In cancer, metabolic profiling may help decipher the vicious interactions established by MM cells with
the bone environment, possibly amenable to therapeutic manipulation. High-resolution magic-angle
spinning (HR-MAS) nuclear magnetic resonance (NMR) spectroscopy is becoming a routine technique
for investigating metabolic profiles from ex vivo tissue samples [7–9]. This analytical method takes
advantage of fast acquisition times, minimal sample preparation, and high reproducibility. Moreover,
being spared from destruction, samples analyzed by HR-MAS are available for further analyses, such
as histology, proteomics, or gene expression, thus allowing for direct comparison of data obtained with
different techniques on the same sample [6,10–12]. The possibility to correlate metabolic alterations
and histopathologic features of a surgical tumor specimen may help decipher tumor heterogeneity and
gain better molecular insights into tumor pathogenic mechanisms [5,13]. Indeed, 1 H HR-MAS NMR is
now increasingly used for the characterization of tumor lesions in humans, including brain [14,15],
breast [16], liver [17], colon [18], and prostate cancers [19]. Notably, 1 H HR-MAS NMR has also been
applied to the study of articular cartilage degradation [20], intervertebral disc degeneration [21],
gamma-radiated bones of non-cancer mouse models [22], and human bone mineral tissue [23].
However, to the best of our knowledge, 1 H HR-MAS NMR has never been applied to achieve metabolic
analysis of bone tumor lesions in human patients.
Here, we carried out a proof-of-concept study of the feasibility of 1 H HR-MAS NMR to address
local heterogeneity in cancer-induced osteolysis. To this aim, we analyzed multiple biopsy specimens
from one case of pathological fracture caused by MM. Two macroscopically different types of tissue
were identified within a single specimen of approximately 3 cm diameter, and adjacent muscle was
used as a third region for comparison. Multivariate analyses on normalized metabolite peak integrals
allowed to identify intergroup differences and to cluster samples in accordance with a posteriori
histological findings. To further investigate the relationship between histological and NMR features,
morphological data and metabolite profiling were compared independently of group assignment.
Collectively, our results show that NMR holds potential to complement histological analysis in the
targeted study of cancer osteolytic lesions.
2. Results
2.1. 1 H HR-MAS Spectra Highlight Differences among Multiple Biopsy Specimens
1H

HR-MAS spectra were obtained for seven muscle (group A: A1–A3, A5–A8), seven oily
tumor (group B: B1–B3, B5–B8), and seven calcified tumor (group C: C1, C3–C8) samples (Figure 1A).
As control spectrum we used a mixed muscle-tumor specimen (A4/B4). Figure 1B and Supplementary

Int. J. Mol. Sci. 2016, 17, 1814

3 of 15

Figure S1A show the superposition of the 1 H HR-MAS NOESY spectra of the three different
sample groups and the corresponding average spectra, respectively. Visual inspection of the spectra
highlighted different profiles for the three sample groups in accordance with the classification obtained
by macroscopic examination of the tumor sample prior to insert preparation. In particular, spectra
deriving from muscle samples contained more peaks as compared to tumor or calcified, consistent with
the higher number of metabolites expected for a specimen with high cytoplasmic content (Figure 1A,B,
Supplementary Figure S1A). Spectra were assigned based on previously published data [7,24–27]
(Figure 1C, Supplementary Table S1) and the relative amounts were compared between different groups
(ANOVA) (Supplementary Table S1). As expected, creatine and phosphocreatine were particularly
enriched in muscle samples (p < 0.01) as compared to tumor specimens (groups B or C) (Supplementary
Figure S2 and Table S1). Also taurine, highly abundant in the cytoplasm, was more abundant in muscle
as compared to tumor samples, reflecting its high cytoplasmic content. In contrast, tumor samples
had higher content of glycerolipids at 2.00 and 2.23 ppm (p < 0.05, Supplementary Figure S2 and
Table S1) likely originating either from membrane phospholipids, due to high cancer cellularity, or
from triacylglycerides and fatty acid chains composing lipid droplets.
2.2. Sample Recovery from HR-MAS Rotors Allows Histology and Histomorphometry Analysis
After spectroscopic analysis, we recovered samples for histological analysis. This was feasible
for seven muscle specimens (A1–A3, A5–A8), six out of seven oily (B1–B3, B6–B8), and five out of
eight calcified tumor (C1, C3, C4, C6, C8) samples (100%, 86%, and 63%, respectively). Histology
confirmed all group A samples to be muscle fibers. Most B samples consisted of tightly packed tumor
cells and fatty areas. C samples contained eosinophilic extracellular matter compatible with bone
residues and connective tissue with reduced cellularity. Histological examination also revealed the
erroneous classification of two samples, C8 and B8, which presented a high concentration of small
cells, with a muscle fiber trapped in B8 (as shown below). By applying histomorphometry for each
section, we counted the number of nuclei (Figure 2A) and adipocytes (Figure 2B) or fat droplets and
quantified the areas associated either to fat (Figure 2C) or muscle (Figure 2D). Statistical analysis
of these measurements confirmed significant morphological differences among groups (p < 0.05
by one-way ANOVA/Tukey’s post-test, Figure 2). Group A showed a high concentration of nuclei
(Figure 2A), with each fiber containing on average 200–300 nuclei, arranged on the border of the
fiber in non-damaged tissue. Little variability was noted in this group, accounted for by few artifacts,
and by the sporadic presence of suffering fibers with centralized nuclei or loose connective tissue
substitution. Group B showed intense areas of packed tumor cells with a high number of vessels and
with bigger nuclei distributed around fatty areas. These areas of less intense color were immersed in
fibrillar tissue and big fat droplets area, with poorly organized structure and irregular disposition of
collagen fibers. Of note, in group C we also observed the presence of calcified tissue compatible with
bone. In accordance with the calcified nature of the sample, the number of cells and the abundance of
connective tissue were reduced as compared to groups A and B, and Havers channels and osteoclasts
were detected.
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Figure 1. 1H HR-MAS (high-resolution magic-angle spinning) spectra of multiple biopsy specimens.
Figure 1. 1 H HR-MAS (high-resolution magic-angle spinning) spectra of multiple biopsy specimens.
(A) From top to bottom: representative hematoxylin and eosin-stained morphological sections of
(A) From top to bottom: representative hematoxylin and eosin-stained morphological sections of
samples belonging to group A, B, and C, respectively; (B) Overlay of the spectra acquired on the
samples belonging to group A, B, and C, respectively; (B) Overlay of the spectra acquired
on
different specimens; the labels on the right indicate group and sample ID; (C) Representative 1H
the different specimens; the labels on the right indicate group and sample ID; (C) Representative
1D-noesygppr HR-MAS nuclear magnetic resonance (NMR) spectrum of group A sample.
1 H 1D-noesygppr HR-MAS nuclear magnetic resonance (NMR) spectrum of group A sample.
Assignment was made on the basis of literature references [7,22,24–27]. Peaks were calibrated using
Assignment
was made on the basis of literature references [7,22,24–27]. Peaks were calibrated using
DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) peak at 0 ppm as reference. Numbers identify
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Numbers
identify binning
binning regions as listed in Supplementary
Table
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2.3. Unsupervised Multivariate Statistical Analysis of 11 H HR-MAS NMR Data
2.3. Unsupervised Multivariate Statistical Analysis of H HR-MAS NMR Data
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(E)

(F)
Figure 3. Multivariate analysis of NMR spectra and histological features. NOESY spectra acquired
Figure 3. Multivariate analysis of NMR spectra and histological features. NOESY spectra acquired
from samples of different origins were statistically analyzed after binning. Classification of
from samples of different origins were statistically analyzed after binning. Classification of specimens
specimens was based on their morphological appearance at the time of sampling. (A) Score plot
was based on their morphological appearance at the time of sampling. (A) Score plot showing the
showing the first two principal components, with black, red, and green dots, respectively
first two principal components, with black, red, and green dots, respectively corresponding to muscle
corresponding to muscle (group A), oily tumor (group B), and calcified tumor samples (group C).
(group A), oily tumor (group B), and calcified tumor samples (group C). The quality control sample
The quality control sample A4/B4, prepared by mixing muscle and tumor specimens, is colored in
A4/B4, prepared by mixing muscle and tumor specimens, is colored in blue. The oval represents the
blue. The oval represents the 95% confidence interval of the analysis; (B) Loadings plot of the
95% confidence interval of the analysis; (B) Loadings plot of the analysis performed in (A). Profiled
analysis performed in (A). Profiled bucket metabolites and their ppm values are shown for those
bucket metabolites and their ppm values are shown for those regions displaying loadings responsible
regions displaying loadings responsible for separation along the first two principal components
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Figure 4. Integrated correlation analysis of histomorphometry and 1H HR-MAS NMR profiling data.

Figure 4. Integrated correlation analysis of histomorphometry 1and 1 H HR-MAS NMR profiling data.
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As in previous analyses, NMR metabolic data were normalized to the sum of intensities and
Pareto-scaled (see Methods for details). The two datasets were then merged, and a correlation matrix
was obtained based on Spearman rank-order correlation. Considering the correlation matrix generated
using all types of samples (Figure 4A) we observed that typical intracellular and cytosolic metabolites
(e.g., taurine, creatine, phosphocreatine, glutamate, glutamine and glycine) correlate with the presence
of muscle fibers in the specimen. Conversely, lipidic regions correlate with fat area and number of
adipocytes. Similar correlations were observed when only muscle samples were analyzed (Figure 4B).
Interestingly, analysis of tumor samples alone highlighted a specific correlation between lipids at
2.75 ppm, 2.23 ppm, and 2.0 ppm, with fat area and adipocytes that were not present in muscle samples
alone, suggesting a different lipidic composition in tumor specimens (Figure 4C). Taken together, our
data indicate a good concordance between morphological and chemical shift features, which could be
exploited to predict tissue composition on the basis of 1 H HR-MAS spectra, or to increase the specificity
of metabolomic analyses on intact tissue.
3. Discussion
We have analyzed multiple biopsy specimens from one case of a pathological fracture caused by
MM to evaluate the feasibility of an integrated approach combining 1 H HR-MAS and multivariate
analysis with histomorphological information to study osteolytic lesions. To our knowledge, this is the
first study using 1 H HR-MAS NMR to investigate human bone cancer biology, as previous applications
of the technique have been reported only on human bone mineral or on bones of non-cancer mouse
models [22,23]. The aim of this study was therefore to verify whether 1 H HR-MAS is applicable to
human bone tumor samples, and whether it is able to highlight differences among specimens sampled
in morphologically different but anatomically close areas. Multivariate analysis of the 1 H HR-MAS
NMR spectra acquired on the biopsies showed that the main spectral differences between muscle
(group A) and tumor tissues (groups B and C) concern the glycogen–glucose region at around 3.7 ppm
and the fatty acids methyl groups resonating at 1.3 ppm. The high content of carbohydrates in group
A most likely derives from glycogen stored in muscle cells, whereas the fatty acids methyl groups,
highly present in the heterogeneous tumor samples, might originate from either phospholipids of
membrane-rich tissue with high cellular density, or from triacylglycerides and/or fatty acid chains
composing lipid droplets. Notably, subsequent histomorphometric analysis highlighted a high cellular
content in districts defined as oily as opposed to calcified ones, but it was not possible to appreciate
significant differences in the fat areas of the two tumor sample groups. Accordingly, both univariate
(Supplementary Table S1) and multivariate analysis (data not shown) of 1 H HR-MAS data were
not able to discriminate between oily and calcified tumors, yet lipid composition appeared slightly
different, as suggested by the peak at 2.75 ppm that was significantly lower in the calcified tumor
samples as compared to the oily ones (Supplementary Table S1 and Figure S2). Interestingly, correlation
matrices between morphological and NMR features hinted at the possible origin of lipidic differences
within tumor specimens (Figure 4C). For example, lipid peaks resonating at 2.75 ppm, 2.23 ppm, and
2.00 ppm were part of a cluster that strongly correlated with the number of adipocytes and fat area.
In line with this observation, several spectroscopic studies have highlighted differences in the lipid
compositions in tumor cells and tissues, as observed, for example, in malignant human renal tissues or
human brain tumor biopsies [30,31]. Our proof-of-principle study of intralesion heterogeneity was not
designed to identify metabolites capable of discriminating different tumor areas. Indeed, the lipidic
differences observed between the two morphologically distinct areas of the tumor were not significant
(see Supplementary Table S1), with the notable exception of lipid 2.75, which suggests the existence of
a differential lipid composition in morphologically distinct tumor areas.
In perspective, the use of larger cohorts of heterogeneous bone lesions of different origins could
help determine how different lipidic signals corresponding to either phospholipids (cell membrane) or
triglycerides (adipocyte-rich fat areas) discriminate different lesion areas or tumor types, providing
relevant information on cancer biology.
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In highly heterogeneous tissues, such as bone tumors and metastases, interpretation of data
deriving from homogenizing or otherwise destructive procedures can be extremely challenging, due
to the different cellular populations and local conditions involved. Our work offers proof-of-concept
evidence that the histological assessment of bone cancer can be integrated with intact-tissue
1 H HR-MAS NMR that enables unbiased metabolic analysis by excluding misclassified samples
and by correlating tissue composition to specific spectral features. Although our data were collected
from a single tumor, our study demonstrates the feasibility of combining HR-MAS and histology
studies on patient-derived bone tumor samples. Future work is required to validate this approach
for the study of cancer metabolism and response to treatments, in order to gain deeper insight in
bone tumor biology. Attesting to clinical translatability, 1 H HR-MAS, thanks to its execution rapidity
and capacity to preserve samples for further analyses, has already shown promising results in other
cancers. For example, it has been successfully adopted to determine sample quality in real-time
during surgery [32], or to aid diagnosis in tumor biopsies [12,33,34]. In the field of bone cancer, further
studies may extend 1 H HR-MAS analyses to larger patient cohorts to characterize and compare
pathologic conditions.
Moreover, the general concordance between metabolic fingerprinting and tissue composition may
offer valuable clinical applications, helping to rapidly and efficiently select significant samples for
pathological analysis (e.g., to avoid areas of necrosis or reactive tissue). The examination of relatively
small amounts of tumor tissues could then be used to assess slight differences in the biochemical
profile of the tissue samples prior to histopathology. In this respect, 1 H HR-MAS NMR spectroscopy is
increasingly emerging as a highly versatile tool [6,11,13–15,17,18].
In conclusion, herein we have shown that human bone cancer specimens can be analyzed
to obtain reproducible 1 H HR-MAS NMR spectra, and then fixed to produce histological slides
spanning the entire sample area. Multivariate analyses on normalized metabolite peak integrals
showed samples to cluster in accordance with a posteriori histological findings, and identified
intergroup differences. Integrating metabolic profiling and histomorphometry is a promising approach
to address heterogeneous bone tumor lesions, establish relevant correlations between metabolic and
morphological features, and develop translatable fingerprinting strategies.
Overall, our work provides proof-of-principle evidence in support of a novel, unbiased, rapid,
and inexpensive approach that may help the assessment of skeletal areas of cancer-induced osteolysis,
providing information of potential biomedical, prognostic and therapeutic value.
4. Materials and Methods
4.1. Case History and Sampling
A 68-year-old female, with no previous history of malignancy, was admitted to the San Raffaele
Orthopaedics Unit for pathological fracture of the left femur of undetermined origin. Conventional
radiographies showed a displaced subtrochanteric fracture, with multiple fragments and possible
extra-osseous involvement, and diffuse bone loss. A 99Tc-MDP (technetium-99 conjugated with
methylene diphosphonate) bone scan showed only little accumulation at the site of fracture, and lack
of tracer accumulation at distant sites suspect for bone lesions. Creatinine and calcium levels were
normal (0.93 mg/dL and 1.83 mmol/L), and the finding of anemia was partially explained by the
presence of trauma. Upon serum protein electrophoresis (SPEP) a monoclonal peak was identified
and quantified over 35 g/L. The later-confirmed diagnosis was IgGK myeloma with 46% of bone
marrow clonal plasma cells and multiple bone lesions. Because of the pathological fracture, the patient
underwent resection and prosthetic replacement of the proximal femur, with good functional results on
mobility and reduction of pain. During surgical procedure, biopsy specimens were collected from the
osteolytic lesion and the surrounding muscle, immediately snap-frozen in liquid nitrogen, and stored
at −80 ◦ C. Sampling was performed during the resection phase, with no requirement for additional
procedures, nor prolongation of surgery. Informed consent was obtained in accordance with the
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declaration of Helsinki. Approval for primary sample use was obtained from the Institutional Review
Board of the San Raffaele Scientific Institute.
4.2. Sample Preparation for NMR
One bulk tumor sample of approximately 3 cm diameter and one small piece of skeletal muscle
were thawed in a cold chamber on ice; once softened, they were cut to small representative specimens.
The tumor sample, upon longitudinal cut, was composed of two types of tissue: an inner core, with
calcified matter suggesting residual bone, and a stereotyped white matter that prevailed at the sample
periphery. The specimens (24 in total) were then divided into three groups: muscle (A1–A8), oily
tumor (B1–B8), and calcified tumor (C1–C8). Scalpel-cut pieces (~10 mg each) were inserted in
standard Kel-F disposable inserts (35 µL internal volume) for 4 mm zirconium oxide Bruker rotors
(80 µL internal volume) together with 5–10 µL DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) in D2 O
necessary for referencing and lock routine, sealed and stored at −80 ◦ C. We also generated an average
sample (termed “control”) combining specimens from group A (muscle sample expected to be rich
in hydrophilic metabolites) and B (tumor area expected to be rich in lipids). To this end, we mixed
samples A4 and B4 in one insert. The total number of inserts analyzed was thus 23. Kel-F disposable
inserts have a low proton background and higher chemical and biological inertness, and are equipped
with a taper and a screw cap ensuring tissue isolation and preservation.
4.3. 1 H HR-MAS NMR
1H

HR-MAS NMR spectra were acquired on an FT-NMR AvanceTM 500 (Bruker BioSpin GmbH,
Rheinstetten, Germany) with a superconducting ultrashield magnet of 11.7 tesla (1 H frequency:
500.13 MHz) located in the Big Instrument Center (C.I.G.A.), of the University of Milano. HR-MAS
NMR spectra were acquired using a sample spinning rate of 4 kHz. Spectra were acquired at 4 ◦ C
(±0.1 ◦ C) to preserve sample integrity and minimize tissue degradation. The temperature was under
control of the BVT 3000 Unit (Bruker BioSpin GmbH, Rheinstetten, Germany). The temperature
control was calibrated with an internal standard considering the real rotor internal temperature, at the
same MAS speed. 1 H NMR data were acquired using two different pulse sequences (Supplementary
Figure S1B): (i) the 1D pulse sequence version of NOESY, with double solvent presaturation during
relaxation delay and during mixing time (noesypr1d), with an effective capability of residual tissue
water signal elimination, with low influence to vicinal metabolites signals, thus allowing minimum
spectrum artefacts and good resolution; (ii) T2-filtered Carr–Purcell–Meiboom–Gill (CPMG) pulse
sequence acquisition [90 − (δ − 180 − δ)]n , to consistently reduce the line-broadening effects deriving
from short T2 components, with standard water presaturation (cpmgpr1d). The two sequences yielded
similar spectral resolution. As expected, the CPMG spectra were characterized by reduced peak
intensities. However, peak positions, binning regions, and peak behavior along the series of CPMG
spectra (group A, B, C) did not change with respect to the NOESY spectra, thus yielding PCA score
plots comparable to the ones obtained from the NOESY spectra. Further statistical analyses were
therefore performed on the NOESY datasets. All spectra were acquired with the following parameters:
90◦ pulse of ~20.5 µs (optimized on different set of samples), spectral width of 5.5 kHz (corresponding
to 11 ppm), acquisition size and time of 32 K and 3 s, respectively. The relaxation delay was set to
5 s; the number of scans was 120, the mixing time in the NOESY experiment was 60 ms. In the case
of cpmg1d pulse sequence, additional parameters were: interpulse delay δ = 1 ms, repetition value
L2 = 20, resulting in a total filter time of 40 ms (2δ × L2). Insert corresponding to sample C2 failed to
fit into the rotor due to insert deformation, and hence was not analyzed by NMR.
4.4. Binning and Profiling
NOESY and CPMG spectra series were processed with MestReNova software version 8.0.2
(Mestrelab Research S.L., Santiago de Compostela, Spain). Spectra were imported, visualized in
stacked mode, and automatically phase-corrected with global and metabonomics algorithms. Stacked
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spectra were apodized along t1 with +1 Hz line broadening and 1 Hz Gaussian bell. Baselines were
corrected using fully automatic Whittaker Smoother method; chemical shifts were calibrated on the
alanine doublet at 1.46 ppm. In the stacked mode visualization 23 integrals were defined in the
spectral region between 0 and 4.5 ppm. Variable binning was applied recursively over all stacked
spectra and absolute integrals were output in a matrix with a suitable format for normalization and
statistical analysis. Both NOESY and CPMG matrices were composed by 23 variables (bins) and
22 rows (i.e., spectra acquired on 21 samples and 1 control sample composed by mixed muscle-tumor
specimen A4/B4). On the basis of already published chemical shift assignments in 1 H HR-MAS
NMR [7,24–27] we have associated each variable binning region to the metabolites contributing to the
integral (Supplementary Table S1).
4.5. Statistical Analyses of NMR Data
4.5.1. Univariate Analysis
Peak integrals deriving from NOESY spectra were normalized to the sum of all interval regions
for each spectrum and Pareto-scaled. Descriptive statistics, one-way ANOVA with Tukey’s multiple
comparison test, linear correlation and regression tests were performed using R statistical suite
(http://www.r-project.org/). Mixed muscle tumor specimens (A4/B4) were excluded from the
univariate analysis.
4.5.2. Multivariate Analysis
Multivariate statistical analysis through principal component analysis (PCA) was performed
using Simca 13.0 software (Umetrics, Umea, Sweden). PCA was applied on the data matrix described
above (23 variables and 22 samples). Negative integrals deriving from spectral regions with imperfect
baseline correction were changed to 0 values. Normalization was achieved by dividing each integral
region by the sum of all interval regions for each spectrum. The normalized integrals were analyzed
by PCA after Pareto-scaling of the data. PCA analysis included also the mixed muscle tumor specimen
(A4/B4).
4.6. Histology and Histomorphometry
Samples deriving from 1 H HR-MAS analysis were recovered from the rotors and embedded
in formalin for subsequent histological analysis. Briefly, formalin-fixed samples were rinsed with
sodium cacodylate (0.02% and 0.01% overnight), EDTA 0.14% 30 min, and neutral-buffered formalin
10% for 2 days, embedded in paraffin, cut to 5 µm sections with a microtome (Leica 3200, Leica
Microsystems GmbH, Wetzlar, Germany) with free floating technique and polylisinate glass (Menzel
Glaser, Braunschweig, Germany). After rehydration in warm water, sections were dried on a hot
plate, washed with alcohol series (xylene 100%, xylene 50% in ethanol (ETOH), ETOH 100%, ETOH
95%, ETOH 85%, ETOH 70%) and water, stained with hematoxylin and eosin Y (Bio-Optica, Milano,
Italy), dehydrated with an alcohol series (ETOH 70%, ETOH 85%, ETOH 95%, ETOH 100%, xylene
50% in ETOH, xylene 100%) and mounted on coverslips with a DPX mounting medium. Images were
taken with Axioplan2, Leica Microsystem (Alembic, San Raffaele Scientific Institute, Milano, Italy).
Nuclei and adipocytes were counted manually and areas of interest measured with ImageJ software
(developed at the National Institutes of Health (Bethesda, MA, USA) available at http://rsb.info.nih.
gov/ij/), then normalized by total section area (in pixels). For grouped analyses (ANOVA, charts),
histomorphometric data were normalized to pixel area and scaled to range. The mixed muscle-tumor
specimen (A4/B4) was excluded from the analysis. Descriptive statistics, one-way ANOVA with
Tukey’s multiple comparison test, linear correlation, and regression tests were performed using R
statistical suite (http://www.r-project.org/).
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4.7. Correlation Analyses
Normalization and correlation analysis between NMR features and histomorphometry data were
performed using the MetaboAnalyst tool suite (http://www.metaboanalyst.ca) [35]. For metabolites,
raw data deriving from the NOESY spectra were normalized by normalizing to the sum of all interval
regions and Pareto-scaling. Histomorphometry data were independently normalized to area and scaled
to range. Normalized data from the two methods were then merged in one matrix set, and then
analyzed with Spearman rank-order correlation. We used only information that was confirmed by
NMR and histological classification, and excluded outliers (C8, B8), mixed muscle-tumor specimen
(A4/B4), as well as misclassified samples C3 and A6 (see Results).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/11/1814/s1.
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